Vivacitas Oncology Inc

Home
United States
Walnut Creek, CA
Vivacitas Oncology Inc

Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from Vivacitas Oncology Inc, Medical and health, Walnut Creek, CA.

Vivacitas is a private clinical-stage biopharmaceutical company focused on developing next-generation oncological therapies and re-designing current treatments that, even when efficacious, are overshadowed by their toxic effects on patients.

11/08/2022

Most cancers of the stomach (about 90% to 95%) are adenocarcinomas. These cancers develop from the gland cells in the innermost lining of the stomach (the mucosa).

If you are told you have (or gastric cancer), it will almost always be an adenocarcinoma.

There are 2 main types of stomach adenocarcinomas:

🔹The intestinal type tends to have a slightly better prognosis (outlook). The cancer cells are more likely to have certain gene changes that might allow for treatment with targeted drug therapy.

🔹The diffuse type tends to grow spread more quickly. It is less common than the intestinal type, and it tends to be harder to treat.

Other types of that can start in the stomach include gastrointestinal stromal tumors (GISTs), neuroendocrine tumors and lymphomas.

10/12/2022

It's simple: early detection = better outcome possibilities.

Help us fight breast cancer by spreading the importance of self-examination!

Besides self-exams, don't forget to get checked at least once a year! Mammography can detect tumors before they can be felt, so regular screening tests are key to a timely diagnosis.

10/07/2022

Scientists often measure the growth rate of a tumor in doubling time, which is how long it takes for a group of cancer cells to double in size.

A 2019 study found that the median doubling time of NSCLC was 230 days. Some tumors studied doubled their size in as few as 19 days, but others never grew that much.

The researchers divided the study participants into two groups: those whose tumors had doubling times of 400 days or more, and those whose tumors had doubling times of fewer than 400 days. Participants in the group with shorter doubling times were more likely to be male and older.

In contrast, a 2020 review lists the doubling time for small cell lung cancer ( ) as 86 days.

This is a race against cancer, and we’re in it to win it!

10/05/2022

Last Saturday, we were honored to present at the 2022 Sino-American Pharmaceutical Professionals Association (SAPA) Conference.

Scott VanderMeer, MBA, Interim CEO, CFO, Director & Co-Founder of Vivacitas Oncology, gave a 20-minute presentation and held a Q&A at the event. “It was great to be back at SAPA for the second year in a row to connect with world-class professionals and to speak with investors about our progress over the last year", he stated.

Read the full press release here: https://www.vivaoncology.com/vivacitas-oncology-presents-for-the-second-year-in-a-row-at-the-2022-sapa-conference/

09/29/2022

Dr. Thomas Gruber, a neurosurgeon at Baptist Health Paducah, was the first neurosurgeon in Kentucky to use a new headlamp device to help air the removal of glioma that result from .

Patients ingest a drug known as Gleolan, which makes the tumor glow a bright, hot pink when viewed under the blue light of a headlamp during surgery. This makes the tumors stand out from healthy brain cells, Gruber said, and helps neurosurgeons make sure they are removing as much of the cancerous cells as possible.

Gruber added: “This provides a whole level of information we didn’t have, where we can see tumors that we literally couldn’t see before, and you can keep working until all the pink stuff goes away.”

09/26/2022

These are some factors that could increase your risk of developing .

Some you can control, some not, but the rule of thumb is to always keep a healthy diet, exercise regularly, watch your weight and avoid the abuse of substances such as alcohol or to***co.

Share the information with someone who needs it!

09/21/2022

In a paper published in Gastroenterology, researchers identified a genetic variation that could help identify when patients with Helicobacter pylori are more likely to develop stomach cancer.

The National Cancer Institute cites infection with H. pylori as the primary identified cause of certain types of stomach cancer. H. pylori is a bacterium that grows in the membrane layer that lines the stomach.

In the United States, H. pylori is more prevalent in Hispanics, African Americans and the elderly. Dr. Merchant cited data suggesting that 1-3% of people with H. pylori will develop and that the cure rate is around 30%, which is low compared with some other types of cancer.

At Vivacitas, we’re working to increase that rate and change the odds for the better, but we couldn’t do it without our fellow colleagues making advancements in parallel! Thank you!

09/13/2022

Our scientists, clinicians, industry executives, and medical advisors came together with a shared mission: to improve the lives of patients by gaining power over the disease.

Each is an accomplished professional and their combined expertise is a force de rigueur in combating the hardest-to-treat cancers.

Vivacitas applies integrity, clarity, tenacity, collaboration, and teamwork to pursue superior results in the lives of cancer patients.

Visit our website to learn more: https://www.vivaoncology.com

09/08/2022

Scientists from The Institute of Cancer Research, UK, have shown it is possible to reverse a key process that allows pancreatic cancer cells to grow and spread around the body.

These findings, which were published in Nature, showed that a protein called GREM1 is key to regulating a type of cells found in pancreatic cancer—manipulating its levels can both fuel and reverse the ability of these cells to change into a more aggressive subtype.

The researchers believe this fundamental discovery could ultimately pave the way for new pancreatic cancer treatments, and so do we!

Want to stay updated on news? Follow us!

08/01/2022

We’re tirelessly working to offer better solutions to the millions diagnosed every year with this type of cancer and we deeply appreciate all of our colleagues fighting for the same cause.

07/06/2022

In a new study led by investigators at Brigham and Women's Hospital and Medical School, scientists devised a novel therapeutic strategy that demonstrated profound efficacy in preclinical models of (GBM), with 100 percent of mice living over 90 days after treatment.

Many cell-based therapies for are derived from a patient's own stem cells or immune cells. However, in a disease like , most patients undergo surgery in the first week after receiving their diagnosis due to the disease's rapid progression, granting little time to develop therapeutics from their own cell types.

Instead, scientists developed a novel approach to use or cells from healthy individuals so that the remedy is readily available to administer immediately the time of surgery.

Great job, peers!

07/04/2022

Today we celebrate all the individuals who have fought for our independence while acknowledging there is still a long path to walk.

As for us, we hope to keep honoring our ancestors by fighting for patients' rights who need us to develop better treatment options.

Happy !

06/30/2022

Surgery is the first-line treatment for patients with solid tumors. However, often cells can be left behind and, over time, lead to cancer recurring.

Recently, researchers from the University of Wisconsin-Madison developed drug-releasing hydrogel patches that can be applied post-surgery to prevent or slow tumor recurrence.

They found that the gel could reduce biomarkers of cancer recurrence in mice, specifically those with , , and triple-negative .

Clinical trials are still needed to see whether these results translate over to humans, but we're thankful to see so many advances on the medical field we're so passionate about.

06/23/2022

The second asset in our scientific pipeline is Rubitecan, a second-generation oral Camptothecin. The oral-based Camptothecin treatment was acquired by Vivacitas after having been given to over 900 patients, and showing promising results as a second line of defense therapy.

The next stages in clinical development are currently being evaluated.

Don't miss any updates: https://www.vivaoncology.com/rubitecan/

06/21/2022

Vivacitas was formed in 2015, with the vision of our founders and Dr. Joseph Rubinfeld (co-founder of Amgen).

Since then, we've lived to our mission of creating new treatment options and improving the lives of cancer patients with solid tumors worldwide.

06/19/2022

We're thankful for the many fathers in our team, who work day and night to honor their families along with the patients we dream to help.

!

06/16/2022

Northwestern Medicine scientists have discovered a new biomarker to identify which patients with GBM might benefit from immunotherapy.

The treatment could extend survival for an estimated 20% to 30% of patients. Currently, patients with glioblastoma do not receive this life-prolonging treatment because it has not been fully understood which of them could benefit.

The immunotherapy response marker still needs to be validated in a clinical trial to make sure the study findings are applicable to any glioblastoma patient, said Dr. Adam Sonabend, the senior/corresponding author of this study.

We can't wait for the validation to come through!

06/14/2022

Natural killer cells (often called NK) are a type of white blood cells that can kill tumor cells or cells infected with a virus without any priming or prior activation (in contrast to cytotoxic T cells, which need priming by antigen presenting cells). They are named after this ‘natural’ killing behavior.

NK cells are one of the protagonists of our immune system and they control several types of tumors and microbial infections by limiting their spread and subsequent tissue damage.

They play a big role taking care of our wellbeing and for that they're deeply appreciated!

Address

Walnut Creek, CA

Telephone

+17087109200

Website

https://www.vivaoncology.com/contact-us/

Alerts

Be the first to know and let us send you an email when Vivacitas Oncology Inc posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Vivacitas Oncology Inc:

Shortcuts

Want your practice to be the top-listed Clinic in Walnut Creek?